Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics, Inc.

EV Therapeutics develops off-the-shelf neoantigen-based immunotherapies from tumor-derived extracellular vesicles (EVs) and formulates proprietary therapeutic vaccines to enhance cancer treatment efficacy. self-described.

EV Therapeutics

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Xynomic Pharmaceuticals Holdings, Inc.

Fate Therapeutics is a biopharmaceutical company focused on developing cellular immunotherapies for cancer and autoimmune disorders.

Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

California Institute for Regenerative Medicine

Silicon Valley Bank

Sanofi Ventures

Venrock

ARCH Venture Partners

OVP Venture Partners

Astellas Venture Management

Polaris Partners

Fate Therapeutics Inc.

The Fate Therapeutics Inc. team gathered again for our annual Field Day. We hit the sports courts for some friendly competition, with colleagues showing off their skills in lively challenges designed by our partners at Exos. The weather was on our side, but it was the company spirit that truly shined. 

We wrapped up the day with a fun-filled happy hour, celebrating our incredible team and the vibrant culture that makes Fate Therapeutics such a great place to be!

Have you been wondering about CAR T cells and lupus? Fate Therapeutics Inc. is excited to share that we’ve started an iPSC-derived CAR T cell program for patients with active lupus. To learn more visit:
Study Details | FT819 in Moderate to Severe Active Systemic Lupus Erythematosus | https://lnkd.in/gaDGjYCv

Fate Therapeutics Inc. was proud to recognize Mental Health Awareness Month by hosting an uplifting all-company luncheon! Joined by our partners from Cigna Healthcare and Marsh McLennan, we shared information about the many mental health and wellness resources nestled within our benefits plan, including access to Headspace, Talkspace, and Happify. 

We enjoyed fresh food followed by friendly matches in our Game Area and patio to revitalize our spirits. Our Exos fitness center yoga instructor shared mindfulness and relaxation tips, guiding our team as they crafted their own essential oil blends in the Fate Zen Den. Here’s to fostering a culture of well-being and support! 

#MentalHealthMatters #EmployeeWellness

This week we announced pricing of $100M in financing!

Fate Therapeutics Inc was proud to sponsor and join patients, caregivers, and supporters at The Leukemia & Lymphoma Society's Light The Night Walk in San Diego on November 4th. 

Through bake sales and donations, Team Fate united to raise funds to support research and treatment for patients with blood cancers. Together we bring light to the darkness of cancer. 

#lightthenight #cancerresearch

The Fate Therapeutics Team came together to embrace the spirit of competition and camaraderie on our annual Field Day. Through sports challenges and friendly contests, we celebrated our collective strength and the bond that fuels our shared journey. 

Then we cooled down at the Science Fair where our R&D and Clinical team members shared posters that they presented at the latest scientific conferences. 

Through triumphs and challenges, we stand strong, pushing forward with a collective determination that fuels our mission to transform the lives of patients with cancer and autoimmune disorders.

Metric
Company Name	Fate Therapeutics, Inc.	EV Therapeutics	Therini Bio	Xynomic Pharmaceuticals Holdings, Inc.
Symbol	FATE
MSH ID	COM:FATETHERAPEUTICS	COM:EVTHERAPEUTICS	COM:THERINIBIO	COM:XYNOMICPHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Pharmaceuticals
Country	US	US	US	US
Stage				Series B
Employee Count	181	1
Website	fatetherapeutics.com	evtherapeutics.com	therinibio.com	xynomicpharma.com
LinkedIn	fate-therapeutics-inc		therinibio
Founders

Metric
Market Cap	355.16M
Enterprise Value
Monthly Web Traffic		1.52K
Web Traffic Growth		4.19
Valuation
Raised Capital

Metric
Revenue	63.53M
Revenue (LTM)
Revenue (NTM)
Gross Profit	45.25M
EBITDA	-159.33M
Operating Income	-177.61M
Net Income	-160.93M
EPS	-1.64
Diluted EPS	-1.64
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.71
Operating Profit Margin	-3.00
EBITDA Margin	-2.51
Net Profit Margin	-2.38
Return on Equity	-0.36
Return on Assets	-0.30
Return on Capital Employed	-0.40

COM:FATETHERAPEUTICS

Fate Therapeutics

Last Close

2.07

22/11 21:00

Market Cap

355.16M

Beta: -

Volume Today

652

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.06
P/B Ratio	1.57
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	100.51
EV Multiple	-1.50

Metric
Days Sales Outstanding	5.29
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	99.05
Cash Conversion Cycle	-23.21
Asset Turnover	0.13

Metric
Operating Cash Flow	-132.26M
Free Cash Flow	-138.42M
Cash Flow to Debt	-1.08
Operating Cash Flow/Sales	-2.08
Free Cash Flow Yield	-0.29

Metric
Cash & Equivalents	41.87M
Accounts Receivable	36.65M
Inventory
Goodwill
Debt to Capitalization	0.22
Debt to Assets	0.19
Current Ratio	8.81
Quick Ratio	9.18

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.50
R&D to Revenue	2.15
SG&A to Revenue	0.80